Janssen Pharmaceuticals

The United States Judicial Panel on Multi-District Litigation (MDL) recently convened to determine whether the cases, known as IN RE: XARELTO (RIVAROXABAN)

PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat).

Since its approval, there have been numerous reports of

Xarelto is marketed as an anticoagulant prescribed to reduce the risk of stroke, deep-vein thrombosis and pulmonary embolism. It is manufactured in the United States by Bayer and Johnson & Johnson’s New Jersey-based division, Janssen Pharmaceuticals. Lawsuits have been filed nationwide based on claims that Xarelto is responsible for injuries in some individuals.

Lawsuits allege